Drug Makers Designing Better Ingredients For Hep C Drug Cocktails
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As the field of hepatitis C therapy opens up with the specifically targeted antiviral therapies for HCV, the combination of drugs used to treat the chronic disease will be in flux. While the likely key ingredients are pretty well known, and for the immediate future will retain an interferon/ribavirin backbone, a few smaller companies are starting to demonstrate what they can add to the mix